Skip to main content
BF Biosciences Limited logo

BF Biosciences Limited — Investor Relations & Filings

Ticker · BFBIO ISIN · PK0148201012 PSX Manufacturing
Open in API
Filings indexed 33 across all filing types
Latest filing 2026-04-30 Interim / Quarterly Rep…
Country PK Pakistan
Listing PSX BFBIO

About BF Biosciences Limited

http://bfbio.com/

BF Biosciences Limited is a pioneering biotech pharmaceutical company engaged in the import, manufacturing, marketing, and distribution of pharmaceutical products. The company specializes in state-of-the-art biotechnology, offering life-saving drugs for conditions such as cardiovascular diseases, breast cancer, diabetes mellitus, chronic kidney diseases, and rheumatoid arthritis. Operating as a joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina, BF Biosciences serves markets including Pakistan, Nepal, Afghanistan, and other international regions, built upon a foundation of trust and credibility.

Recent filings

Filing Released Lang Actions
Transmission of Quarterly Report for the Period Ended 31-03-2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Financial Information For The Nine Months Ended 31 March 2026' and contains detailed financial statements including statement of financial position, profit or loss, comprehensive income, changes in equity, cash flows, and notes. It also includes a Directors' Review Report and financial highlights for the nine months and third quarter ended 31 March 2026. The presence of actual financial data and analysis for a period shorter than a full fiscal year (nine months) clearly indicates this is an interim or quarterly report. The document length is substantial (15,000 characters) and contains the full report, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2026-04-30 English
Financial Results for the Quarter Ended 31-03-2026
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial statements including a Condensed Interim Statement of Financial Position, Profit or Loss, Comprehensive Income, Changes in Equity, and Cash Flows for the nine months and quarter ended 31 March 2026. The presence of unaudited interim financial data for a period shorter than a full fiscal year, along with comparative figures for the previous year, indicates this is a comprehensive interim financial report. The document length is over 13,000 characters, and it includes substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-04-28 English
Half Yearly Progress Report - For the Period Ended 31 December 2025
Regulatory Filings
2026-04-17 English
Resignation of Director
Regulatory Filings
2026-03-04 English
Transmission of Quarterly Financial Statements for the Period Ended 31-12-2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Financial Information For The Half Year Ended 31 December 2025' and contains detailed financial statements such as the statement of financial position, profit or loss, and notes to the condensed interim financial statements. It includes a Directors' Review Report, an Independent Auditor's Review Report, and comprehensive financial data for the six months ended 31 December 2025. The length of the document is substantial (15,000 characters), and it contains actual financial data and analysis for a period shorter than a full fiscal year (half-year). Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-02-27 English
Financial Results for the Quarter Ended 31-12-2025
Regulatory Filings
2026-02-26 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.